March 26, 2013 at 08:10 AM EDT
Oculus Innovative Granted Reclassification for Microcyn-Based Advanced Wound Management Products in Europe
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS ) a healthcare company a global healthcare company that designs, manufactures and markets prescription and non-prescription products in over 20 countries, today announced that is has been granted a reclassification of the company's CE Mark for the European formulation Dermacyn™ Wound Care. The reclassification was approved by the British Standards
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here